




Expert

ICD-10-CM Expert for Physicians

The complete official guidelines and code set

Codes valid from October 1, 2026
through September 30, 2027



Contents

How to Use ICD-10-CM Expert for Physicians 2027	iii		
Introduction	iii	Chapter 12. Diseases of the Skin and Subcutaneous Tissue (L00–L99)	745
What's New for 2027.....	iii	Chapter 13. Diseases of the Musculoskeletal System and Connective Tissue (M00–M99)	767
Conversion Table	iii	Chapter 14. Diseases of Genitourinary System (N00–N99).....	857
10 Steps to Correct Coding.....	iii	Chapter 15. Pregnancy, Childbirth, and the Puerperium (O00–O9A).....	879
Official ICD-10-CM Guidelines for Coding and Reporting	iii	Chapter 16. Certain Conditions Originating in the Perinatal Period (P00–P96)	919
Indexes	iii	Chapter 17. Congenital Malformations, Deformations, and Chromosomal Abnormalities (Q00–Q99)	933
Index to Diseases and Injuries	iii	Chapter 18. Symptoms, Signs, and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified (R00–R99)	953
Neoplasm Table.....	iii	Chapter 19. Injury, Poisoning, and Certain Other Consequences of External Causes (S00–T88)	975
Table of Drugs and Chemicals	iii	Chapter 20. External Causes of Morbidity (V00–Y99)	1175
External Causes Index	iii	Chapter 21. Factors Influencing Health Status and Contact with Health Services (Z00–Z99)	1241
Index Notations	iv	Chapter 22. Codes for Special Purposes (U00–U85)	1281
Tabular List of Diseases	v		
Code and Code Descriptions.....	v		
Tabular Notations	v		
Official Notations	v		
Optum Notations	vi		
Icons	vi		
Color Bars	vii		
Chapter-Level Notations	vii		
Appendices	viii		
Illustrations.....	viii		
What's New for 2027	ix	Appendices	Appendices-1
Official Updates	ix	Appendix A: Valid 3-character ICD-10-CM Codes	Appendices-1
Proprietary Updates	ix	Appendix B: Pharmacology List 2027.....	Appendices-3
Conversion Table of ICD-10-CM Codes	x	Appendix C: Z Codes for Long-Term Drug Use with Associated Drugs	Appendices-18
10 Steps to Correct Coding.....	xii	Appendix D: Z Codes Only as Principal/First-Listed Diagnosis	Appendices-20
ICD-10-CM Official Guidelines for Coding and Reporting	Coding Guidelines-1	Appendix E: Centers for Medicare & Medicaid Services Hierarchical Condition Categories (CMS-HCC)	Appendices-21
ICD-10-CM Index to Diseases and Injuries	1	Appendix F: Centers for Medicare & Medicaid Services Quality Payment Program.....	Appendices-23
ICD-10-CM Neoplasm Table	339		
ICD-10-CM Table of Drugs and Chemicals	358		
ICD-10-CM Index to External Causes.....	408		
ICD-10-CM Tabular List of Diseases and Injuries	445		
Chapter 1. Certain Infectious and Parasitic Diseases (A00–B99), U07.1, U09.9	445	Chapter 3. Diseases of the Blood and Blood-forming Organs and Certain Disorders Involving the Immune Mechanism (D50–D89)	Illustrations-1
Chapter 2. Neoplasms (C00–D49)	471	Red Blood Cells..... Illustrations-1	
Chapter 3. Diseases of the Blood and Blood-forming Organs and Certain Disorders Involving the Immune Mechanism (D50–D89)	513	White Blood Cell..... Illustrations-1	
Chapter 4. Endocrine, Nutritional, and Metabolic Diseases (E00–E89)	527	Platelet	Illustrations-2
Chapter 5. Mental, Behavioral, and Neurodevelopmental Disorders (F01–F99)	553	Coagulation..... Illustrations-2	
Chapter 6. Diseases of the Nervous System (G00–G99).....	585	Spleen Anatomical Location and External Structures	Illustrations-3
Chapter 7. Diseases of the Eye and Adnexa (H00–H59).....	609	Spleen Interior Structures..... Illustrations-3	
Chapter 8. Diseases of the Ear and Mastoid Process (H60–H95)	645	Chapter 4. Endocrine, Nutritional, and Metabolic Diseases (E00–E89)	Illustrations-4
Chapter 9. Diseases of the Circulatory System (I00–I99)	657	Endocrine System	Illustrations-4
Chapter 10. Diseases of the Respiratory System (J00–J99), U07.0	703	Thyroid	Illustrations-5
Chapter 11. Diseases of the Digestive System (K00–K95)	719	Thyroid and Parathyroid Glands	Illustrations-5
		Pancreas	Illustrations-6
		Anatomy of the Adrenal Gland	Illustrations-6
		Structure of an Ovary	Illustrations-7
		Testis and Associated Structures	Illustrations-7
		Thymus	Illustrations-8
		Chapter 6. Diseases of the Nervous System (G00–G99)	Illustrations-9
		Brain	Illustrations-9
		Cranial Nerves	Illustrations-9
		Peripheral Nervous System	Illustrations-10
		Spinal Cord and Spinal Nerves	Illustrations-11
		Nerve Cell	Illustrations-12
		Trigeminal and Facial Nerve Branches	Illustrations-12

Chapter 7. Diseases of the Eye and Adnexa (H00–H59).....	Illustrations–13
Eye.....	Illustrations–13
Posterior Pole of Globe/Flow of Aqueous Humor	Illustrations–13
Lacrimal System.....	Illustrations–14
Eye Musculature	Illustrations–14
Eyelid Structures.....	Illustrations–14
Chapter 8. Diseases of the Ear and Mastoid Process (H60–H95).....	Illustrations–15
Ear Anatomy	Illustrations–15
Chapter 9. Diseases of the Circulatory System (I00–I99).....	Illustrations–16
Anatomy of the Heart	Illustrations–16
Heart Cross Section.....	Illustrations–16
Heart Valves.....	Illustrations–17
Heart Conduction System	Illustrations–17
Coronary Arteries	Illustrations–18
Arteries.....	Illustrations–19
Veins.....	Illustrations–20
Internal Carotid and Vertebral Arteries and Branches	Illustrations–21
External Carotid Artery and Branches.....	Illustrations–21
Branches of Abdominal Aorta	Illustrations–22
Portal Venous Circulation.....	Illustrations–22
Lymphatic System.....	Illustrations–23
Axillary Lymph Nodes	Illustrations–24
Lymphatic System of Head and Neck	Illustrations–24
Lymphatic Capillaries.....	Illustrations–25
Lymphatic Drainage	Illustrations–25
Chapter 10. Diseases of the Respiratory System (J00–J99), U07.0.....	Illustrations–26
Respiratory System	Illustrations–26
Upper Respiratory System	Illustrations–27
Lower Respiratory System	Illustrations–27
Paranasal Sinuses	Illustrations–27
Lung Segments	Illustrations–28
Alveoli	Illustrations–28
Chapter 11. Diseases of the Digestive System (K00–K95).....	Illustrations–29
Digestive System	Illustrations–29
Omentum and Mesentery	Illustrations–30
Peritoneum and Retroperitoneum	Illustrations–30
Chapter 12. Diseases of the Skin and Subcutaneous Tissue (L00–L99)	Illustrations–31
Nail Anatomy	Illustrations–31
Skin and Subcutaneous Tissue	Illustrations–31
Chapter 13. Diseases of the Musculoskeletal System and Connective Tissue (M00–M99)	Illustrations–32
Bones and Joints	Illustrations–32
Shoulder Anterior View	Illustrations–33
Shoulder Posterior View	Illustrations–33
Elbow Anterior View	Illustrations–33
Elbow Posterior View	Illustrations–33
Hand	Illustrations–33
Hip Anterior View	Illustrations–34
Hip Posterior View	Illustrations–34
Knee Anterior View	Illustrations–34
Knee Posterior View	Illustrations–34
Foot	Illustrations–34
Muscles	Illustrations–35
Chapter 14. Diseases of Genitourinary System (N00–N99)	Illustrations–36
Urinary System	Illustrations–36
Male Genitourinary System	Illustrations–37
Female Internal Genitalia	Illustrations–37
Female Genitourinary Tract Lateral View	Illustrations–37
Chapter 15. Pregnancy, Childbirth, and the Puerperium (O00–O9A)	Illustrations–38
Term Pregnancy – Single Gestation	Illustrations–38
Twin Gestation–Dichorionic–Diamniotic (DI-DI)	Illustrations–38
Twin Gestation–Monochorionic–Diamniotic (MO-DI)	Illustrations–39
Twin Gestation–Monochorionic–Monoamniotic (MO-MO)	Illustrations–39
Chapter 19. Injury, Poisoning, and Certain Other Consequences of External Causes (S00–T88)	Illustrations–40
Types of Fractures	Illustrations–40
Salter-Harris Fracture Types	Illustrations–40

How to Use ICD-10-CM Expert for Physicians 2027

Introduction

ICD-10-CM Expert for Physicians: The Complete Official Code Set is your definitive coding resource, combining the work of the National Center for Health Statistics (NCHS), Centers for Medicare and Medicaid Services (CMS), American Hospital Association (AHA), and Optum experts to provide the information you need for coding accuracy.

The International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM), is an adaptation of ICD-10, copyrighted by the World Health Organization (WHO). The development and maintenance of this clinical modification (CM) is the responsibility of the NCHS as authorized by WHO. Any new concepts added to ICD-10-CM are based on an established update process through the collaboration of WHO's Update and Revision Committee and the ICD-10-CM Coordination and Maintenance Committee.

In addition to the ICD-10-CM classification, other official government source information has been included in this manual. Depending on the source, updates to information may be annual or quarterly. This manual provides the most current information that was available at the time of publication. For updates to the source documents that may have occurred after this manual was published, please refer to the following:

- **NCHS, International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)**
<https://www.cms.gov/medicare/coding-billing/icd-10-codes/2025-icd-10-cm>
- **CMS Integrated Outpatient Code Editor (IOCE), version 25.2**
<https://www.cms.gov/Medicare/Coding/OutpatientCodeEdit/OCEQtrReleaseSpecs.html>
- **CMS-HCC Risk Adjustment Model, version 28**
- **CMS ESRD-HCC Risk Adjustment Model, version 24**
- **CMS RxHCC Risk Adjustment Model, version 08**
<https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Risk-Adjustors.html>
- **HHS-HCC Commercial Risk Adjustment Model, version 07**
<https://www.cms.gov/CCIO/Resources/Regulations-and-Guidance>
- **CMS Quality Payment Program (QPP)**
<https://qpp.cms.gov/mips/explore-measures>
- **AHA Coding Clinics**
<https://www.codingclinicadvisor.com/>

Significant updates to this manual will be provided on our product updates page at Optumcoding.com, which can be accessed at the following:

<https://www.optumcoding.com/ProductUpdates/>
 Password: XXXXXX

The official NCHS ICD-10-CM classification includes three main sections: the guidelines, the indexes, and the tabular list, all of which make up the bulk of this coding manual. To complement the classification, Optum's coding experts have incorporated Medicare-related coding edits and proprietary features, such as supplementary notations, coding tools, and appendixes, into a comprehensive and easy-to-use reference. This publication is organized as follows:

What's New for 2025

This section provides a high-level overview of the code changes made for fiscal 2025. The list of codes provided identifies new, revised, and deleted codes. Asterisked codes identify prior midyear changes that were made to

the classification, effective April 1, 2024. All changes are based on official addenda, provided by the NCHS.

Conversion Table

The conversion table was developed by NCHS to help facilitate data retrieval as new codes are added to the ICD-10-CM classification. This table provides a crosswalk from each fiscal 2025 new code to the equivalent code(s) assigned, prior to October 1, 2024, for that diagnosis or condition. Asterisked codes identify prior midyear additions, effective April 1, 2024. For the full conversion table, refer to the Conversion Table zip file at <https://www.cms.gov/medicare/coding-billing/icd-10-codes/2025-icd-10-cm>.

10 Steps to Correct Coding

This step-by-step tutorial walks the coder through the process of finding the correct code — from locating the code in the official indexes to verifying the code in the tabular section — while following applicable conventions, guidelines, and instructional notes. Specific examples are provided with detailed explanations of each coding step along with advice for proper sequencing.

Official ICD-10-CM Guidelines for Coding and Reporting

This section provides the full official conventions and guidelines regulating the appropriate assignment and reporting of ICD-10-CM codes. These conventions and guidelines are published by the U.S. Department of Health and Human Services (DHHS) and approved by the cooperating parties (American Health Information Management Association [AHIMA], NCHS, Centers for Disease Control and Prevention [CDC], and the American Hospital Association [AHA]).

Indexes

Index to Diseases and Injuries

The Index to Diseases and Injuries is arranged in alphabetic order by terms specific to a disease, condition, illness, injury, eponym, or abbreviation as well as terms that describe circumstances other than a disease or injury that may require attention from a health care professional.

Neoplasm Table

The Neoplasm Table is arranged in alphabetic order by anatomical site. Codes are then listed in individual columns based upon the histological behavior (malignant, in situ, benign, uncertain, or unspecified) of the neoplasm.

Table of Drugs and Chemicals

The Table of Drugs and Chemicals is arranged in alphabetic order by the specific drug or chemical name. Codes are listed in individual columns based upon the associated intent (poisoning, adverse effect, or underdosing). Drugs with an asterisk identify substances added to the table by Optum subject matter experts.

External Causes Index

The External Causes Index is arranged in alphabetic order by main terms that describe the cause, the intent, the place of occurrence, the activity, and the status of the patient at the time the injury occurred or health condition arose.

ICD-10-CM Index to Diseases and Injuries

A

Aarskog's syndrome Q87.19
Abandonment — see Maltreatment
Abasia (-astasia) (hysterical) F44.4
Abderhalden-Kaufmann-Lignac syndrome (cystinosis) E72.04
Abdomen, abdominal — see also condition
 acute R10.0
 angina K55.1
 muscle deficiency syndrome Q79.4
Abdominalgia — see Pain, abdominal
Abduction contracture, hip or other joint — see Contracture, joint
Aberrant (congenital) — see also Malposition, congenital
 adrenal gland Q89.1
 artery (peripheral) Q27.8
 basilar NEC Q28.1
 cerebral Q28.3
 coronary Q24.5
 digestive system Q27.8
 eye Q15.8
 lower limb Q27.8
 precerebral Q28.1
 pulmonary Q25.79
 renal Q27.2
 retina Q14.1
 specified site NEC Q27.8
 subclavian Q27.8
 upper limb Q27.8
 vertebral Q28.1
 breast Q83.8
 endocrine gland NEC Q89.2
 hepatic duct Q44.5
 pancreas Q45.3
 parathyroid gland Q89.2
 pituitary gland Q89.2
 sebaceous glands, mucous membrane, mouth, congenital Q38.6
 spleen Q89.09
 subclavian artery Q27.8
 thymus (gland) Q89.2
 thyroid gland Q89.2
 vein (peripheral) NEC Q27.8
 cerebral Q28.3
 digestive system Q27.8
 lower limb Q27.8
 precerebral Q28.1
 specified site NEC Q27.8
 upper limb Q27.8
Aberration
 distastial — see Disturbance, visual mental F99
Abetalipoproteinemia E78.6
Abiotrophy R68.89
Ablatio, ablation
 retinae — see Detachment, retina
Ablepharia, ablepharon Q10.3
Abnormal, abnormality, abnormalities — see also
 Anomaly
 acid-base balance (mixed) E87.4
 albumin R77.0
 alphafetoprotein R77.2
 alveolar ridge K08.9
 anatomical relationship Q89.9
 apertures, congenital, diaphragm Q79.1
 atrial septal, specified NEC Q21.19
 auditory perception H93.29-
 diploacus — see Diploacus
 hyperacusis — see Hyperacusis
 recruitment — see Recruitment, auditory threshold shift — see Shift, auditory threshold
 autosomes Q99.9
 fragile site Q95.5
 basal metabolic rate R94.8
 biosynthesis, testicular androgen E29.1
 bleeding time R79.1
 blood amino-acid level R79.83
 blood level (of)
 cobalt R79.0
 copper R79.0
 iron R79.0

Abnormal, abnormality, abnormalities — continued
 blood level — continued
 lithium R78.89
 magnesium R79.0
 mineral NEC R79.0
 zinc R79.0
 blood pressure
 elevated R03.0
 low reading (nonspecific) R03.1
 blood sugar R73.09
 blood-gas level R79.81
 bowel sounds R19.15
 absent R19.11
 hyperactive R19.12
 brain scan R94.02
 breathing R06.9
 caloric test R94.138
 cerebrospinal fluid R83.9
 cytology R83.6
 drug level R83.2
 enzyme level R83.0
 hormones R83.1
 immunology R83.4
 microbiology R83.5
 nonmedicinal level R83.3
 specified type NEC R83.8
 chemistry, blood R79.9
 C-reactive protein R79.82
 drugs — see Findings, abnormal, in blood
 gas level R79.81
 minerals R79.0
 pancytopenia D61.818
 PTT R79.1
 specified NEC R79.89
 toxins — see Findings, abnormal, in blood
 chest sounds (friction) (rales) R09.89
 chromosome, chromosomal Q99.9
 with more than three X chromosomes, female Q97.1
 analysis result R89.8
 bronchial washings R84.8
 cerebrospinal fluid R83.8
 cervix uteri NEC R78.89
 nasal secretions R84.8
 nipple discharge R89.8
 peritoneal fluid R85.89
 pleural fluid R84.8
 prostatic secretions R86.8
 saliva R85.89
 seminal fluid R86.8
 sputum R84.8
 synovial fluid R89.8
 throat scrapings R84.8
 vagina R87.89
 vulva R87.89
 wound secretions R89.8
 dicentriate replacement Q93.2
 ring replacement Q93.2
 sex Q99.8
 female phenotype Q97.9
 specified NEC Q97.8
 male phenotype Q98.9
 specified NEC Q98.8
 structural male Q98.6
 specified NEC Q99.8
 clinical findings NEC R68.89
 coagulation D68.9
 newborn, transient P61.6
 profile R79.1
 time R79.1
 communication — see Fistula
 conjunctiva, vascular H11.41-
 coronary artery Q24.5
 cortisol-binding globulin E27.8
 course, eustachian tube Q17.8
 creatinine clearance R94.4
 cytology
 anus R85.619
 atypical squamous cells cannot exclude high grade squamous intraepithelial lesion (ASC-H) R85.611
 atypical squamous cells of undetermined significance (ASC-US) R85.610
 cytologic evidence of malignancy R85.614
Abnormal, abnormality, abnormalities — continued
 cytology — continued
 anus — continued
 high grade squamous intraepithelial lesion (HSIL) R85.613
 human papillomavirus (HPV) DNA test
 high risk positive R85.81
 low risk positive R85.82
 inadequate smear R85.615
 low grade squamous intraepithelial lesion (LSIL) R85.612
 satisfactory anal smear but lacking transformation zone R85.616
 specified NEC R85.618
 unsatisfactory smear R85.615
 female genital organs — see Abnormal, Papanicolaou (smear)
 dark adaptation curve H53.61
 dentofacial NEC — see Anomaly, dentofacial development, developmental Q89.9
 central nervous system Q07.9
 diagnostic imaging
 abdomen, abdominal region NEC R93.5
 biliary tract R93.2
 bladder R93.41
 breast R92.8
 central nervous system NEC R90.89
 cerebrovascular NEC R90.89
 coronary circulation R93.1
 digestive tract NEC R93.3
 gastrointestinal (tract) R93.3
 genitourinary organs R93.89
 head R93.0
 heart R93.1
 intrathoracic organ NEC R93.89
 kidney R93.42-
 limbs R93.6
 liver R93.2
 lung (field) R91.8
 musculoskeletal system NEC R93.7
 renal pelvis R93.41
 retroperitoneum R93.5
 site specified NEC R93.89
 skin and subcutaneous tissue R93.89
 skull R93.0
 testis R93.81-
 ureter R93.41
 urinary organs specified NEC R93.49
 direction, teeth, fully erupted M26.30
 ear ossicles, acquired NEC H74.39-
 ankylosis — see Ankylosis, ear ossicles
 discontinuity — see Discontinuity, ossicles, ear
 partial loss — see Loss, ossicles, ear (partial)
 Ebstein Q22.5
 echocardiogram R93.1
 echoencephalogram R90.81
 echogram — see Abnormal, diagnostic imaging
 electrocardiogram [ECG] [EKG] R94.31
 electroencephalogram [EEG] R94.01
 electrolyte — see Imbalance, electrolyte
 electromyogram [EMG] R94.131
 electro-oculogram [EOG] R94.110
 electrophysiological intracardiac studies R94.39
 electroretinogram [ERG] R94.111
 erythrocytes
 congenital, with perinatal jaundice D58.9
 feces (color) (contents) (mucus) R19.5
 finding — see Findings, abnormal, without diagnosis fluid
 amniotic — see Abnormal, specimen, specified
 cerebrospinal — see Abnormal, cerebrospinal fluid
 peritoneal — see Abnormal, specimen, digestive organs
 pleural — see Abnormal, specimen, respiratory organs
 synovial — see Abnormal, specimen, specified
 thorax (bronchial washings) (pleural fluid) — see Abnormal, specimen, respiratory organs
 vaginal — see Abnormal, specimen, female genital organs
 form
 teeth K00.2
 uterus — see Anomaly, uterus

	Malignant Primary	Malignant Secondary	Ca in situ	Benign	Uncertain Behavior	Unspecified Behavior		Malignant Primary	Malignant Secondary	Ca in situ	Benign	Uncertain Behavior	Unspecified Behavior
Neoplasm, neoplastic — continued							Neoplasm, neoplastic — continued						
brain — <i>continued</i>							bronchus — <i>continued</i>						
basal ganglia	C71.0	C79.31	—	D33.0	D43.0	D49.6	main	C34.0-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1
cerebellopontine angle	C71.6	C79.31	—	D33.1	D43.1	D49.6	middle lobe of lung	C34.2	C78.0-✓	D02.21	D14.31	D38.1	D49.1
cerebellum NOS	C71.6	C79.31	—	D33.1	D43.1	D49.6	overlapping lesion	C34.8-✓	—	—	—	—	—
cerebrum	C71.0	C79.31	—	D33.0	D43.0	D49.6	upper lobe of lung	C34.1-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1
choroid plexus	C71.7	C79.31	—	D33.1	D43.1	D49.6	brow	C44.309	C79.2	D04.39	D23.39	D48.5	D49.2
corpus callosum	C71.8	C79.31	—	D33.2	D43.2	D49.6	basal cell carcinoma	C44.319	—	—	—	—	—
corpus striatum	C71.0	C79.31	—	D33.0	D43.0	D49.6	specified type NEC	C44.399	—	—	—	—	—
cortex (cerebral)	C71.0	C79.31	—	D33.0	D43.0	D49.6	squamous cell carcinoma	C44.329	—	—	—	—	—
frontal lobe	C71.1	C79.31	—	D33.0	D43.0	D49.6	buccal (cavity)	C06.9	C79.89	D00.00	D10.39	D37.09	D49.0
globus pallidus	C71.0	C79.31	—	D33.0	D43.0	D49.6	commissure	C06.0	C79.89	D00.02	D10.39	D37.09	D49.0
hippocampus	C71.2	C79.31	—	D33.0	D43.0	D49.6	groove (lower) (upper)	C06.1	C79.89	D00.02	D10.39	D37.09	D49.0
hypothalamus	C71.0	C79.31	—	D33.0	D43.0	D49.6	mucosa	C06.0	C79.89	D00.02	D10.39	D37.09	D49.0
internal capsule	C71.0	C79.31	—	D33.0	D43.0	D49.6	sulcus (lower) (upper)	C06.1	C79.89	D00.02	D10.39	D37.09	D49.0
medulla							bulbourethral gland	C68.0	C79.19	D09.19	D30.4	D41.3	D49.59
oblongata	C71.7	C79.31	—	D33.1	D43.1	D49.6	bursa — <i>see</i> Neoplasm, connective tissue						
meninges	C70.0	C79.32	—	D32.0	D42.0	D49.7	buttock NEC	C76.3	C79.89	D04.5	D36.7	D48.7	D49.89
midbrain	C71.7	C79.31	—	D33.1	D43.1	D49.6	calf	C76.5-✓	C79.89	D04.7-✓	D36.7	D48.7	D49.89
occipital lobe	C71.4	C79.31	—	D33.0	D43.0	D49.6	calvarium	C41.0	C79.51	—	D16.4	D48.0	D49.2
overlapping lesion	C71.8	C79.31	—	—	—	—	calyx, renal canal	C65.-✓	C79.0-✓	D09.19	D30.1-✓	D41.1-✓	D49.51-✓
parietal lobe	C71.3	C79.31	—	D33.0	D43.0	D49.6	anal	C21.1	C78.5	D01.3	D12.9	D37.8	D49.0
peduncle	C71.7	C79.31	—	D33.1	D43.1	D49.6	auditory (external) — <i>see also</i> Neoplasm, skin, ear						
pons	C71.7	C79.31	—	D33.1	D43.1	D49.6	auricular (external) — <i>see also</i> Neoplasm, skin, ear	C44.20-✓	C79.2	D04.2-✓	D23.2-✓	D48.5	D49.2
stem	C71.7	C79.31	—	D33.1	D43.1	D49.6	canalicular, biliary (biliferi) (intrahepatic)						
tapetum	C71.8	C79.31	—	D33.2	D43.2	D49.6	canthus (eye) (inner) (outer)	C22.1	C78.7	D01.5	D13.4	D37.6	D49.0
temporal lobe	C71.2	C79.31	—	D33.0	D43.0	D49.6	basal cell carcinoma	C44.10-✓	C79.2	D04.1-✓	D23.1-✓	D48.5	D49.2
thalamus	C71.0	C79.31	—	D33.0	D43.0	D49.6	sebaceous cell carcinoma	C44.11-✓	—	—	—	—	—
uncus	C71.2	C79.31	—	D33.0	D43.0	D49.6	specified type NEC	C44.13-✓	—	—	—	—	—
ventricle (floor) fourth	C71.5	C79.31	—	D33.0	D43.0	D49.6	squamous cell carcinoma	C44.19-✓	—	—	—	—	—
branchial (cleft) (cyst) (vestiges)	C71.7	C79.31	—	D33.1	D43.1	D49.6	capillary — <i>see</i> Neoplasm, connective tissue						
breast (connective tissue) (glandular tissue) (soft parts)	C10.4	C79.89	D00.08	D10.5	D37.05	D49.0	caput coli	C18.0	C78.5	D01.0	D12.0	D37.4	D49.0
areola	C50.9-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	carcinoïd — <i>see</i> Tumor, carcinoid						
axillary tail	C50.0-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	cardia (gastric)	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
central portion	C50.6-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	cardiac orifice (stomach)	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
inner	C50.1-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	cardio-esophageal junction	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
lower	C50.8-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	cardio-esophagus	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
lower-inner quadrant	C50.3-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	carina (bronchus)	C34.0-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1
lower-outer quadrant	C50.5-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	carotid (artery) body	C49.0	C79.89	—	D21.0	D48.1-✓	D49.2
mastectomy site (skin) — <i>see also</i> Neoplasm, breast, skin							carpus (any bone)	C75.4	C79.89	—	D35.5	D44.6	D49.7
specified as breast tissue							cartilage (articular) (joint) NEC — <i>see also</i> Neoplasm, bone	C40.1-✓	C79.51	—	D16.1-✓	—	—
midline	C50.8-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	arytenoid	C41.9	C79.51	—	D16.9	D48.0	D49.2
nipple	C50.0-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	auricular	C32.3	C78.39	D02.0	D14.1	D38.0	D49.1
outer overlapping lesion	C50.8-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	bronchi	C34.0-✓	C78.39	—	D21.0	D48.1-✓	D49.2
skin							costal	C41.3	C79.51	—	D16.7	D48.0	D49.2
basal cell carcinoma	C44.501	C79.2	D04.5	D23.5	D48.5	D49.2	cricoid	C32.3	C78.39	D02.0	D14.1	D38.0	D49.1
specified type NEC							cuneiform	C32.3	C78.39	D02.0	D14.1	D38.0	D49.1
squamous cell carcinoma							ear (external)	C49.0	C79.89	—	D21.0	D48.1-✓	D49.2
tail (axillary)	C50.6-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	ensiform	C41.3	C79.51	—	D16.7	D48.0	D49.2
upper	C50.8-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3	epiglottis	C32.1	C78.39	D02.0	D14.1	D38.0	D49.1
upper-inner quadrant	C50.2-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3							
upper-outer quadrant	C50.4-✓	C79.81	D05.-✓	D24.-✓	D48.6-✓	D49.3							
broad ligament	C57.1-✓	C79.82	D07.39	D28.2	D39.8	D49.59							
bronchiogenic, bronchogenic (lung)	C34.9-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							
bronchiale	C34.9-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							
bronchus	C34.9-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							
carina	C34.0-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							
lower lobe of lung	C34.3-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							

☒ Additional Character Required — Refer to the Tabular List for Character Selection

Substance	Poisoning, Accidental (unintentional)	Poisoning, Intentional Self-harm	Poisoning, Assault	Poisoning, Undetermined	Adverse Effect	Under-dosing	Substance	Poisoning, Accidental (unintentional)	Poisoning, Intentional Self-harm	Poisoning, Assault	Poisoning, Undetermined	Adverse Effect	Under-dosing
Androstalone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthiolimine	T37.4X1	T37.4X2	T37.4X3	T37.4X4	T37.4X5	T37.4X6
Androstanolone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthralin	T49.4X1	T49.4X2	T49.4X3	T49.4X4	T49.4X5	T49.4X6
Androsterone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthramycin	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
Anemone pulsatilla	T62.2X1	T62.2X2	T62.2X3	T62.2X4	—	—	Antidiuretic NEC	T44.8X1	T44.8X2	T44.8X3	T44.8X4	T44.8X5	T44.8X6
Anesthesia							Antiallergic NEC	T45.0X1	T45.0X2	T45.0X3	T45.0X4	T45.0X5	T45.0X6
caudal	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antiandrogen NEC	T38.6X1	T38.6X2	T38.6X3	T38.6X4	T38.6X5	T38.6X6
endotracheal	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6	Anti-anemic (drug) (preparation)	T45.8X1	T45.8X2	T45.8X3	T45.8X4	T45.8X5	T45.8X6
epidural	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antianxiety drug NEC	T43.501	T43.502	T43.503	T43.504	T43.505	T43.506
inhalation	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6	Antiaris toxicaria	T65.891	T65.892	T65.893	T65.894	—	—
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antiarteriosclerotic drug	T46.6X1	T46.6X2	T46.6X3	T46.6X4	T46.6X5	T46.6X6
mucosal	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antiasthmatic drug NEC	T48.6X1	T48.6X2	T48.6X3	T48.6X4	T48.6X5	T48.6X6
muscle relaxation	T48.1X1	T48.1X2	T48.1X3	T48.1X4	T48.1X5	T48.1X6	Antibiotic Otic Suspension (Solution)*	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
nerve blocking	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
plexus blocking	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
potentiated	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
rectal	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
regional	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
surface	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
Anesthetic NEC — see also Anesthesia	T41.41	T41.42	T41.43	T41.44	T41.45	T41.46							
with muscle relaxant	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
gaseous NEC	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6							
general NEC	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
halogenated hydrocarbon derivatives NEC	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6							
infiltration NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
intravenous NEC	T41.1X1	T41.1X2	T41.1X3	T41.1X4	T41.1X5	T41.1X6							
local NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
rectal	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206							
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
regional NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
spinal NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
thiobarbiturate	T41.1X1	T41.1X2	T41.1X3	T41.1X4	T41.1X5	T41.1X6							
topical	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6							
Aneurine	T45.2X1	T45.2X2	T45.2X3	T45.2X4	T45.2X5	T45.2X6							
Angeliq*	T38.5X1	T38.5X2	T38.5X3	T38.5X4	T38.5X5	T38.5X6							
Angio-Conray	T50.8X1	T50.8X2	T50.8X3	T50.8X4	T50.8X5	T50.8X6							
Angiotensin	T44.5X1	T44.5X2	T44.5X3	T44.5X4	T44.5X5	T44.5X6							
Angiotensinamide	T44.991	T44.992	T44.993	T44.994	T44.995	T44.996							
Anhydrohydroxy-progesterone	T38.5X1	T38.5X2	T38.5X3	T38.5X4	T38.5X5	T38.5X6							
Anhydron	T50.2X1	T50.2X2	T50.2X3	T50.2X4	T50.2X5	T50.2X6							
Anileridine	T40.491	T40.492	T40.493	T40.494	T40.495	T40.496							
Aniline (dye) (liquid)	T65.3X1	T65.3X2	T65.3X3	T65.3X4	—	—							
analgesic derivatives, therapeutic NEC	T39.1X1	T39.1X2	T39.1X3	T39.1X4	T39.1X5	T39.1X6							
vapor	T65.3X1	T65.3X2	T65.3X3	T65.3X4	—	—							
Anisocorpine	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6							
Anise oil	T47.5X1	T47.5X2	T47.5X3	T47.5X4	T47.5X5	T47.5X6							
Anisidine	T65.3X1	T65.3X2	T65.3X3	T65.3X4	—	—							
Anisindione	T45.511	T45.512	T45.513	T45.514	T45.515	T45.516							
Anisotropine methyl-bromide	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6							
Anistreplase	T45.611	T45.612	T45.613	T45.614	T45.615	T45.616							
Anorexiant (central)	T50.5X1	T50.5X2	T50.5X3	T50.5X4	T50.5X5	T50.5X6							
Anorexic agents	T50.5X1	T50.5X2	T50.5X3	T50.5X4	T50.5X5	T50.5X6							
Ansaid*	T39.311	T39.312	T39.313	T39.314	T39.315	T39.316							
Ansamycin	T36.6X1	T36.6X2	T36.6X3	T36.6X4	T36.6X5	T36.6X6							
Ant (bite) (sting)	T63.421	T63.422	T63.423	T63.424	—	—							
Antabuse	T50.6X1	T50.6X2	T50.6X3	T50.6X4	T50.6X5	T50.6X6							
Antacid NEC	T47.1X1	T47.1X2	T47.1X3	T47.1X4	T47.1X5	T47.1X6							
Antagonist													
Aldosterone	T50.0X1	T50.0X2	T50.0X3	T50.0X4	T50.0X5	T50.0X6							
alpha-adrenoreceptor	T44.6X1	T44.6X2	T44.6X3	T44.6X4	T44.6X5	T44.6X6							
anticoagulant	T45.7X1	T45.7X2	T45.7X3	T45.7X4	T45.7X5	T45.7X6							
beta-adrenoreceptor	T44.7X1	T44.7X2	T44.7X3	T44.7X4	T44.7X5	T44.7X6							
extrapyramidal NEC	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6							
folic acid	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6							
H2 receptor	T47.0X1	T47.0X2	T47.0X3	T47.0X4	T47.0X5	T47.0X6							
heavy metal	T45.8X1	T45.8X2	T45.8X3	T45.8X4	T45.8X5	T45.8X6							
narcotic analgesic	T50.7X1	T50.7X2	T50.7X3	T50.7X4	T50.7X5	T50.7X6							
opiate	T50.7X1	T50.7X2	T50.7X3	T50.7X4	T50.7X5	T50.7X6							
pyrimidine	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6							
serotonin	T46.5X1	T46.5X2	T46.5X3	T46.5X4	T46.5X5	T46.5X6							
Antazolin (e)	T45.0X1	T45.0X2	T45.0X3	T45.0X4	T45.0X5	T45.0X6							
Anterior pituitary hormone NEC	T38.811	T38.812	T38.813	T38.814	T38.815	T38.816							
Anthelmintic NEC	T37.4X1	T37.4X2	T37.4X3	T37.4X4	T37.4X5	T37.4X6							

ICD-10-CM Tabular List of Diseases and Injuries

Chapter 1. Certain Infectious and Parasitic Diseases (A00–B99), U07.1, U09.9

Chapter-specific Guidelines with Coding Examples

The chapter-specific guidelines from the ICD-10-CM Official Guidelines for Coding and Reporting have been provided below. Along with these guidelines are coding examples, contained in the shaded boxes, that have been developed to help illustrate the coding and/or sequencing guidance found in these guidelines.

a. Human immunodeficiency virus (HIV) infections

1) Code only confirmed cases

Code only confirmed cases of HIV infection/illness. This is an exception to the hospital inpatient guideline Section II, H.

In this context, "confirmation" does not require documentation of positive serology or culture for HIV; the provider's diagnostic statement that the patient is HIV positive or has an HIV-related illness is sufficient.

Patient being seen for hypothyroidism with possible HIV infection

E03.9 Hypothyroidism, unspecified

Explanation: Only the hypothyroidism is coded in this scenario because it has not been confirmed that an HIV infection is present.

2) Selection and sequencing of HIV codes

(a) Patient admitted for HIV-related condition

If a patient is admitted for an HIV-related condition, the principal diagnosis should be B20, Human immunodeficiency virus [HIV] disease followed by additional diagnosis codes for all reported HIV-related conditions.

An exception to this guideline is if the reason for admission is hemolytic-uremic syndrome associated with HIV disease. Assign code D59.31, Infection-associated hemolytic-uremic syndrome, followed by code B20, Human immunodeficiency virus [HIV] disease.

HIV with CMV

B20 Human immunodeficiency virus [HIV] disease

B25.9 Cytomegaloviral disease, unspecified

Explanation: Cytomegaloviral infection is an HIV related condition, so the HIV diagnosis code is reported first, followed by the code for the CMV.

(b) Patient with HIV disease admitted for unrelated condition

If a patient with HIV disease is admitted for an unrelated condition (such as a traumatic injury), the code for the unrelated condition (e.g., the nature of injury code) should be the principal diagnosis. Other diagnoses would be B20 followed by additional diagnosis codes for all reported HIV-related conditions.

Sprain of the internal collateral ligament, right ankle; HIV

S93.491A Sprain of other ligament of right ankle, initial encounter

B20 Human immunodeficiency virus [HIV] disease

Explanation: The ankle sprain is not related to HIV, so it is the first-listed diagnosis code, and HIV is reported secondarily.

(c) Whether the patient is newly diagnosed

Whether the patient is newly diagnosed or has had previous admissions/encounters for HIV conditions is irrelevant to the sequencing decision.

Newly diagnosed multiple cutaneous Kaposi's sarcoma lesions in previously diagnosed HIV disease

B20 Human immunodeficiency virus [HIV] disease

C46.0 Kaposi's sarcoma of skin

Explanation: Even though the HIV was diagnosed on a previous encounter, it is still sequenced first when coded with an HIV-related condition. Kaposi's sarcoma is an HIV-related condition.

(d) Asymptomatic human immunodeficiency virus

Z21, Asymptomatic human immunodeficiency virus [HIV] infection status, is to be applied when the patient without any documentation of symptoms is listed as being "HIV positive," "known HIV," "HIV test positive," or similar terminology. Do not use this code if the term "AIDS" or "HIV disease" is used or if the patient is treated for any

HIV-related illness or is described as having any condition(s) resulting from his/her HIV positive status; use B20 in these cases.

(e) Patients with inconclusive HIV serology

Patients with inconclusive HIV serology, but no definitive diagnosis or manifestations of the illness, may be assigned code R75, Inconclusive laboratory evidence of human immunodeficiency virus [HIV].

(f) Previously diagnosed HIV-related illness

Patients with any known prior diagnosis of an HIV-related illness should be coded to B20. Once a patient has developed an HIV-related illness, the patient should always be assigned code B20 on every subsequent admission/encounter. Patients previously diagnosed with any HIV illness (B20) should never be assigned to R75 or Z21, Asymptomatic human immunodeficiency virus [HIV] infection status.

(g) HIV infection in pregnancy, childbirth and the puerperium

During pregnancy, childbirth or the puerperium, a patient admitted (or presenting for a health care encounter) because of an HIV-related illness should receive a principal diagnosis code of O98.7-, Human immunodeficiency [HIV] disease complicating pregnancy, childbirth and the puerperium, followed by B20 and the code(s) for the HIV-related illness(es). Codes from Chapter 15 always take sequencing priority.

Patients with asymptomatic HIV infection status admitted (or presenting for a health care encounter) during pregnancy, childbirth, or the puerperium should receive codes of O98.7- and Z21.

(h) Encounters for testing for HIV

If a patient is being seen to determine his/her HIV status, use code Z11.4, Encounter for screening for human immunodeficiency virus [HIV]. Use additional codes for any associated high-risk behavior, if applicable.

If a patient with signs or symptoms is being seen for HIV testing, code the signs and symptoms. An additional counseling code Z71.7, Human immunodeficiency virus [HIV] counseling, may be used if counseling is provided during the encounter for the test.

When a patient returns to be informed of his/her HIV test results and the test result is negative, use code Z71.7, Human immunodeficiency virus [HIV] counseling.

If the results are positive, see previous guidelines and assign codes as appropriate.

(i) HIV managed by antiretroviral medication

If a patient with documented HIV disease, HIV-related illness or AIDS is currently managed on antiretroviral medications, assign code B20, Human immunodeficiency virus [HIV] disease. Code Z79.899, Other long term (current) drug therapy, may be assigned as an additional code to identify the long-term (current) use of antiretroviral medications.

(j) Encounter for HIV Prophylaxis Measure

When a patient is seen for administration of pre-exposure prophylaxis medication for HIV, assign code Z29.81, Encounter for HIV pre-exposure prophylaxis. Pre-exposure prophylaxis (PrEP) is intended to prevent infection in people who are at risk for getting HIV through sex or injection drug use. Any risk factors for HIV should also be coded.

b. Infectious agents as the cause of diseases classified to other chapters

Certain infections are classified in chapters other than Chapter 1 and no organism is identified as part of the infection code. In these instances, it is necessary to use an additional code from Chapter 1 to identify the organism. A code from category B95, Streptococcus, Staphylococcus, and Enterococcus as the cause of diseases classified to other chapters, B96, Other bacterial agents as the cause of diseases classified to other chapters, or B97, Viral agents as the cause of diseases classified to other chapters, is to be used as an additional code to identify the organism. An instructional note will be found at the infection code advising that an additional organism code is required.

Acute *E. coli* cystitis

N30.00 Acute cystitis without hematuria

B96.20 Unspecified Escherichia coli [E.coli] as the cause of diseases classified elsewhere

Explanation: An instructional note under the category for the cystitis indicates to code also the specific organism.

F16.921	Hallucinogen use, unspecified with intoxication with delirium	HCC ESR COM
Other hallucinogen intoxication delirium		
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	HCC ESR COM
F16.94 Hallucinogen use, unspecified with hallucinogen-induced mood disorder		
Other hallucinogen induced bipolar or related disorder, without use disorder		
Other hallucinogen induced depressive disorder, without use disorder		
Phencyclidine induced bipolar or related disorder, without use disorder		
Phencyclidine induced depressive disorder, without use disorder		
✓6th F16.95	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder	
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	HCC ESR COM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	HCC ESR COM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	HCC ESR COM
Other hallucinogen induced psychotic disorder, without use disorder		
Phencyclidine induced psychotic disorder, without use disorder		
✓6th F16.98	Hallucinogen use, unspecified with other specified hallucinogen-induced disorder	
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	HCC ESR COM
Other hallucinogen-induced anxiety disorder, without use disorder		
Phencyclidine induced anxiety disorder, without use disorder		
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	HCC ESR COM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	HCC ESR COM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	HCC ESR COM

✓4th F17 Nicotine dependence

EXCLUDES 1 history of tobacco dependence (Z87.891)
tobacco use NOS (Z72.0)
EXCLUDES 2 tobacco use (smoking) during pregnancy, childbirth and the puerperium (O99.33-)
toxic effect of nicotine (T65.2-)

AHA: 2013,4Q,108-109

✓5th F17.2 Nicotine dependence**✓6th F17.20 Nicotine dependence, unspecified****F17.200 Nicotine dependence, unspecified, uncomplicated**Tobacco use disorder, mild
Tobacco use disorder, moderate
Tobacco use disorder, severe

AHA: 2016,1Q,36

TIP: Assign when provider documentation indicates "smoker" without further specification.

F17.201 Nicotine dependence, unspecified, in remission

Tobacco use disorder, mild, in early remission
Tobacco use disorder, mild, in sustained remission
Tobacco use disorder, moderate, in early remission
Tobacco use disorder, moderate, in sustained remission
Tobacco use disorder, severe, in early remission
Tobacco use disorder, severe, in sustained remission

F17.203 Nicotine dependence unspecified, with withdrawal

Tobacco withdrawal

F17.208 Nicotine dependence, unspecified, with other nicotine-induced disorders**F17.209 Nicotine dependence, unspecified, with unspecified nicotine-induced disorders**✓6th F17.21**F17.21 Nicotine dependence, cigarettes****F17.210 Nicotine dependence, cigarettes, uncomplicated**

AHA: 2017,2Q,28-29

F17.211 Nicotine dependence, cigarettes, in remission

Tobacco use disorder, cigarettes, mild, in early remission

Tobacco use disorder, cigarettes, mild, in sustained remission

Tobacco use disorder, cigarettes, moderate, in early remission

Tobacco use disorder, cigarettes, moderate, in sustained remission

Tobacco use disorder, cigarettes, severe, in early remission

Tobacco use disorder, cigarettes, severe, in sustained remission

F17.213 Nicotine dependence, cigarettes, with withdrawal**F17.218 Nicotine dependence, cigarettes, with other nicotine-induced disorders****F17.219 Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders****Nicotine dependence, chewing tobacco****F17.220 Nicotine dependence, chewing tobacco, uncomplicated****F17.221 Nicotine dependence, chewing tobacco, in remission**

Tobacco use disorder, chewing tobacco, mild, in early remission

Tobacco use disorder, chewing tobacco, mild, in sustained remission

Tobacco use disorder, chewing tobacco, moderate, in early remission

Tobacco use disorder, chewing tobacco, moderate, in sustained remission

Tobacco use disorder, chewing tobacco, severe, in early remission

Tobacco use disorder, chewing tobacco, severe, in sustained remission

F17.223 Nicotine dependence, chewing tobacco, with withdrawal**F17.228 Nicotine dependence, chewing tobacco, with other nicotine-induced disorders****F17.229 Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders**✓6th F17.29**F17.29 Nicotine dependence, other tobacco product****F17.290 Nicotine dependence, other tobacco product, uncomplicated**

AHA: 2017,2Q,28-29

F17.291 Nicotine dependence, other tobacco product, in remission

Tobacco use disorder, other tobacco product, mild, in early remission

Tobacco use disorder, other tobacco product, mild, in sustained remission

Tobacco use disorder, other tobacco product, moderate, in early remission


Tobacco use disorder, other tobacco product, moderate, in sustained remission

Tobacco use disorder, other tobacco product, severe, in early remission

Tobacco use disorder, other tobacco product, severe, in sustained remission

F17.293 Nicotine dependence, other tobacco product, with withdrawal**F17.298 Nicotine dependence, other tobacco product, with other nicotine-induced disorders****F17.299 Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders**

I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	HCC Rx ESR COM
	Subsequent acute transmural myocardial infarction of other sites	
	Subsequent apical-lateral transmural (Q wave) myocardial infarction (acute)	
	Subsequent basal-lateral transmural (Q wave) myocardial infarction (acute)	
	Subsequent high-lateral transmural (Q wave) myocardial infarction (acute)	
	Subsequent posterior (true) transmural (Q wave) myocardial infarction (acute)	
	Subsequent posterobasal transmural (Q wave) myocardial infarction (acute)	
	Subsequent posterolateral transmural (Q wave) myocardial infarction (acute)	
	Subsequent posteroseptal transmural (Q wave) myocardial infarction (acute)	
	Subsequent septal NOS transmural (Q wave) myocardial infarction (acute)	
	Subsequent transmural (Q wave) myocardial infarction (acute) (of lateral (wall) NOS	
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	HCC Rx ESR COM
	Subsequent acute myocardial infarction of unspecified site	
	Subsequent myocardial infarction (acute) NOS	
I23	Certain current complications following ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction (within the 28 day period)	
	AHA: 2017,2Q,11	
	DEF: ST elevation myocardial infarction: Complete obstruction of one or more coronary arteries causing decreased blood flow (ischemia) and necrosis of myocardial muscle cells.	
	DEF: Non-ST elevation myocardial infarction: Partial obstruction of one or more coronary arteries that causes decreased blood flow (ischemia) and may cause partial thickness necrosis of myocardial muscle cells.	
I23.0	Hemopericardium as current complication following acute myocardial infarction	HCC Rx ESR COM A
	EXCLUDES 1 hemopericardium not specified as current complication following acute myocardial infarction (I31.2)	
I23.1	Atrial septal defect as current complication following acute myocardial infarction	HCC Rx ESR COM A
	EXCLUDES 1 acquired atrial septal defect not specified as current complication following acute myocardial infarction (I51.0)	
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	HCC Rx ESR COM A
	EXCLUDES 1 acquired ventricular septal defect not specified as current complication following acute myocardial infarction (I51.0)	
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	HCC Rx ESR COM A
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	HCC Rx ESR COM
	EXCLUDES 1 rupture of chordae tendineae not specified as current complication following acute myocardial infarction (I51.1)	
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	HCC Rx ESR COM
	EXCLUDES 1 rupture of papillary muscle not specified as current complication following acute myocardial infarction (I51.2)	
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	HCC Rx ESR COM A
	EXCLUDES 1 thrombosis of atrium, auricular appendage, and ventricle not specified as current complication following acute myocardial infarction (I51.3)	
I23.7	Postinfarction angina	HCC Rx ESR COM A
	AHA: 2015,2Q,16	
	TIP: When postinfarction angina occurs with atherosclerotic coronary artery disease, code both I23.7 and I25.118 for atherosclerotic disease with other forms of angina pectoris.	
I23.8	Other current complications following acute myocardial infarction	HCC Rx ESR COM A

I24	Other acute ischemic heart diseases	HCC Rx ESR COM
	EXCLUDES 1 angina pectoris (I20.-)	
	transient myocardial ischemia in newborn (P29.4)	
	EXCLUDES 2 non-ischemic myocardial injury (I5A)	
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	HCC Rx ESR COM
	Acute coronary (artery) (vein) embolism not resulting in myocardial infarction	
	Acute coronary (artery) (vein) occlusion not resulting in myocardial infarction	
	Acute coronary (artery) (vein) thromboembolism not resulting in myocardial infarction	
	EXCLUDES 1 atherosclerotic heart disease (I25.1-)	
	AHA: 2013,1Q,24	
I24.1	Dressler's syndrome	HCC Rx ESR COM
	Postmyocardial infarction syndrome	
	EXCLUDES 1 postinfarction angina (I23.7)	
	DEF: Fever, leukocytosis, chest pain, evidence of pericarditis, pleurisy, and pneumonia occurring days or weeks after a myocardial infarction.	
I24.8	Other forms of acute ischemic heart disease	
	EXCLUDES 1 myocardial infarction due to demand ischemia (I21.A1)	
	AHA: 2023,4Q,25-26; 2019,4Q,53; 2017,4Q,13	
I24.81	Acute coronary microvascular dysfunction	HCC Rx ESR COM
	Acute (presentation of) coronary microvascular disease	
I24.89	Other forms of acute ischemic heart disease	HCC Rx ESR COM
I24.9	Acute ischemic heart disease, unspecified	HCC Rx ESR COM
	EXCLUDES 1 ischemic heart disease (chronic) NOS (I25.9)	
I25	Chronic ischemic heart disease	
	Use additional code to identify:	
	chronic total occlusion of coronary artery (I25.82)	
	exposure to environmental tobacco smoke (Z77.22)	
	history of tobacco dependence (Z87.891)	
	occupational exposure to environmental tobacco smoke (Z57.31)	
	tobacco dependence (F17.-)	
	tobacco use (Z72.0)	
	EXCLUDES 2 non-ischemic myocardial injury (I5A)	
	AHA: 2022,4Q,20-21	
I25.1	Atherosclerotic heart disease of native coronary artery	
	Atherosclerotic cardiovascular disease	
	Coronary (artery) atheroma	
	Coronary (artery) atherosclerosis	
	Coronary (artery) disease	
	Coronary (artery) sclerosis	
	Use additional code, if applicable, to identify:	
	coronary atherosclerosis due to calcified coronary lesion (I25.84)	
	coronary atherosclerosis due to lipid rich plaque (I25.83)	
	EXCLUDES 2 atheroembolism (I75.-)	
	atherosclerosis of coronary artery bypass graft(s) and transplanted heart (I25.7)	
	Atheromas	
		
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	HCC Rx A
	Atherosclerotic heart disease NOS	
	AHA: 2024,1Q,28; 2021,3Q,6-7; 2015,2Q,16; 2012,4Q,92	
I25.11	Atherosclerotic heart disease of native coronary artery with angina pectoris	
	AHA: 2024,1Q,28	
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	HCC Rx ESR COM A
	EXCLUDES 1 unstable angina without atherosclerotic heart disease (I20.0)	

Muscle/Tendon Table

ICD-10-CM categorizes certain muscles and tendons in the upper and lower extremities by their action (e.g., extension, flexion), their anatomical location (e.g., posterior, anterior), and/or whether they are intrinsic or extrinsic to a certain anatomical area. The Muscle/Tendon Table is provided at the beginning of chapters 13 and 19 as a resource to help users when code selection depends on one or more of these characteristics. A **TIP** has been placed at those categories and/or subcategories that relate to this table. Please note that this table is not all-inclusive, and proper code assignment should be based on the provider's documentation.

Body Region	Muscle	Extensor Tendon	Flexor Tendon	Other Tendon
Shoulder				
	Deltoid	Posterior deltoid	Anterior deltoid	
	Rotator cuff			
	Infraspinatus			Infraspinatus
	Subscapularis			Subscapularis
	Supraspinatus			Supraspinatus
	Teres minor			Teres minor
	Teres major	Teres major		
Upper arm				
	Anterior muscles			
	Biceps brachii — long head		Biceps brachii — long head	
	Biceps brachii — short head		Biceps brachii — short head	
	Brachialis		Brachialis	
	Coracobrachialis		Coracobrachialis	
	Posterior muscles			
Forearm				
	Anterior muscles			
	Flexors			
	Deep			
	Flexor digitorum profundus		Flexor digitorum profundus	
	Flexor pollicis longus		Flexor pollicis longus	
	Intermediate			
	Flexor digitorum superficialis		Flexor digitorum superficialis	
	Superficial			
	Flexor carpi radialis		Flexor carpi radialis	
	Flexor carpi ulnaris		Flexor carpi ulnaris	
	Palmaris longus		Palmaris longus	
	Pronators			
	Pronator quadratus			Pronator quadratus
	Pronator teres			Pronator teres
	Posterior muscles			
	Extensors			
	Deep			
	Abductor pollicis longus			Abductor pollicis longus
	Extensor indicis	Extensor indicis		
	Extensor pollicis brevis	Extensor pollicis brevis		
	Extensor pollicis longus	Extensor pollicis longus		
	Superficial			
	Brachioradialis			Brachioradialis
	Extensor carpi radialis brevis	Extensor carpi radialis brevis		

Chapter 21. Factors Influencing Health Status and Contact With Health Services (Z00-Z99)

NOTE

Z codes represent reasons for encounters. A corresponding procedure code must accompany a Z code if a procedure is performed. Categories Z00-Z99 are provided for occasions when circumstances other than a disease, injury or external cause classifiable to categories A00-Y89 are recorded as "diagnoses" or "problems." This can arise in two main ways:

(a) When a person who may or may not be sick encounters the health services for some specific purpose, such as to receive limited care or service for a current condition, to donate an organ or tissue, to receive prophylactic vaccination (immunization), or to discuss a problem which is in itself not a disease or injury.

(b) When some circumstance or problem is present which influences the person's health status but is not in itself a current illness or injury.

AHA: 2018,4Q,60-61

This chapter contains the following blocks:

- Z00-Z13 Persons encountering health services for examinations
- Z14-Z15 Genetic carrier and genetic susceptibility to disease
- Z16 Resistance to antimicrobial drugs
- Z17 ► Estrogen, and other hormones and factors receptor status◀
- Z18 Retained foreign body fragments
- Z19 Hormone sensitivity malignancy status
- Z20-Z29 Persons with potential health hazards related to communicable diseases
- Z30-Z39 Persons encountering health services in circumstances related to reproduction
- Z40-Z53 Encounters for other specific health care
- Z55-Z65 Persons with potential health hazards related to socioeconomic and psychosocial circumstances
- Z66 Do not resuscitate status
- Z67 Blood type
- Z68 Body mass index (BMI)
- Z69-Z76 Persons encountering health services in other circumstances
- Z77-Z99 Persons with potential health hazards related to family and personal history and certain conditions influencing health status

Persons encountering health services for examinations (Z00-Z13)

NOTE

Nonspecific abnormal findings disclosed at the time of these examinations are classified to categories R70-R94.

EXCLUDES 1 examinations related to pregnancy and reproduction (Z30-Z36, Z39-.)

✓4th Z00 **Encounter for general examination without complaint, suspected or reported diagnosis**

EXCLUDES 1 encounter for examination for administrative purposes (Z02.-)

EXCLUDES 2 encounter for pre-procedural examinations (Z01.81-) special screening examinations (Z11-Z13)

AHA: 2017,4Q,95

✓5th Z00.0 **Encounter for general adult medical examination**

Encounter for adult periodic examination (annual) (physical) and any associated laboratory and radiologic examinations

EXCLUDES 1 encounter for examination of sign or symptom - code to sign or symptom general health check-up of infant or child (Z00.12.-)

Z00.00 **Encounter for general adult medical examination without abnormal findings**

Encounter for adult health check-up NOS

AHA: 2016,1Q,36

Z00.01 **Encounter for general adult medical examination with abnormal findings**

Use additional code to identify abnormal findings

AHA: 2016,1Q,35-36

✓5th Z00.1 **Encounter for newborn, infant and child health examinations**

✓6th Z00.11 **Newborn health examination**

Health check for child under 29 days old

Use additional code to identify any abnormal findings

EXCLUDES 1 health check for child over 28 days old (Z00.12-)

Z00.110 **Health examination for newborn under 8 days old**

Health check for newborn under 8 days old

Z00.111 **Health examination for newborn 8 to 28 days old**

Health check for newborn 8 to 28 days old

Newborn weight check

✓6th Z00.12 **Encounter for routine child health examination**

Health check (routine) for child over 28 days old

Immunizations appropriate for age

Routine developmental screening of infant or child

Routine vision and hearing testing

EXCLUDES 1 health check for child under 29 days old (Z00.11-)

health supervision of foundling or other

healthy infant or child (Z76.1-Z76.2)

newborn health examination (Z00.11-)

AHA: 2018,4Q,36

Z00.121 **Encounter for routine child health examination with abnormal findings**

Use additional code to identify abnormal findings

AHA: 2016,1Q,34-35

Z00.129 **Encounter for routine child health examination without abnormal findings**

Encounter for routine child health examination NOS

AHA: 2016,1Q,34

Z00.2 **Encounter for examination for period of rapid growth in childhood**

PDX P

Z00.3 **Encounter for examination for adolescent development state**

PDX P

Encounter for puberty development state

Z00.5 **Encounter for examination of potential donor of organ and tissue**

PDX P

Examination of participant or control in clinical research program

Z00.6 **Encounter for examination for normal comparison and control in clinical research program**

Examination of participant or control in clinical research program

✓5th Z00.7

Encounter for examination for period of delayed growth in childhood

Z00.70 **Encounter for examination for period of delayed growth in childhood without abnormal findings**

PDX P

Z00.71 **Encounter for examination for period of delayed growth in childhood with abnormal findings**

PDX P

Use additional code to identify abnormal findings

Z00.8 **Encounter for other general examination**

PDX P

Encounter for health examination in population surveys

✓4th Z01 **Encounter for other special examination without complaint, suspected or reported diagnosis**

INCLUDES routine examination of specific system

NOTE Codes from category Z01 represent the reason for the encounter. A separate procedure code is required to identify any examinations or procedures performed

EXCLUDES 1 encounter for examination for administrative purposes (Z02.-)

encounter for examination for suspected conditions, proven not to exist (Z03.-)

encounter for laboratory and radiologic examinations as a component of general medical examinations (Z00.0-)

encounter for laboratory, radiologic and imaging examinations for sign(s) and symptom(s) - code to the sign(s) or symptom(s)

EXCLUDES 2 screening examinations (Z11-Z13)

✓5th Z01.0 **Encounter for examination of eyes and vision**

EXCLUDES 1 examination for driving license (Z02.4)

Z01.00 **Encounter for examination of eyes and vision without abnormal findings**

Encounter for examination of eyes and vision NOS

Z01.01 **Encounter for examination of eyes and vision with abnormal findings**

Use additional code to identify abnormal findings

AHA: 2016,4Q,21

✓6th Z01.02 **Encounter for examination of eyes and vision following failed vision screening**

EXCLUDES 1 encounter for examination of eyes and

vision with abnormal findings (Z01.00)

encounter for examination of eyes and

vision without abnormal findings (Z01.00)

AHA: 2019,4Q,20

Z01.020 **Encounter for examination of eyes and vision following failed vision screening without abnormal findings**

PDX P

Appendix C: Z Codes for Long-Term Drug Use with Associated Drugs

This resource correlates the Z codes that are used to identify current long-term drug use with a list of drugs that are typically categorized to that class of drug. These lists are not all-inclusive, providing only the more commonly used drugs.

Z79.01 Long term (current) use of anticoagulants

Arixtra
Defencath
Eliquis
Fragmin
Heparin
Jantoven
Lovenox
Pradaxa
Savaysa
Warfarin
Xarelto

Z79.02 Long term (current) use of antithrombotics/ antiplatelets

Aggrastat
Angiomax
Argatrobaban
Brilinta
Clopidogrel bisulfate
Effient
Eptifibatide
Persantine
Plavix
Prasugrel

Z79.1 Long term (current) use of non-steroidal anti-inflammatories (NSAID)

Advil
Aleve
Anaprox DS
Arthrotec
Caldolor
Cambia
Celebrex
Daypro
Duexis
Feldene
Ibuprofen
Indocin
Mobic
Motrin IB
Nabumetone
Nalfon
Naprelan
Naprosyn
NeoProfen
Ponstel
Voltaren Arthritis Pain
Zipsor

Z79.2 Long term (current) use of antibiotics

Altabax
Amikacin
Amoxicillin
Ampicillin
Augmentin
Avelox
Azactam
Azithromycin
Bactrim
Biaxin XL
Cefazolin sodium
Cefepime hydrochloride
Cefprozil
Ceftriaxone
Cefuroxime sodium
Centany
Cephalexin
Cipro
Ciprofloxacin
Clarithromycin

Cleocin
Clindamycin
Daptomycin
Difid
Doxycycline
E.E.S.
Ertapenem
ERYC
Erygel
EryPed
Ery-Tab
Erythrocin
Erythromycin
Fetroja
Flagyl
Gentamicin sulfate
Hiprex
Invanz
Isoniazid
Klaron
Lincocin
Macrobid
Macrodantin
Mepron
Merrem
Metronidazole
Minocin
Monodox
Monurol
Mycobutin
Nebupent
Neosporin
Nitrofurantoin
Oracea
Orbactiv
Penicillin-VK
Pentam
Pfizerpen
Priftin
Primaxin
Rifadin
Rimactane
Septra
Seromycin
Silvadene
Sivextro
Solistyn
Solosec
Streptomycin sulfate
Suprax
Synercid
Talicia
Tazicef
Teflaro
Tetracycline
Tobramycin
Trimethoprim
Tygacil
Unasyn
Vabomere
Vancocin HCl
Vancomycin HCl
Vibativ
Vibramycin
Voquezna
Xacduro
Xenleta
Xifaxan
Zerbaxa
Zithromax
Zyvox

Z79.3 Long term (current) use of hormonal contraceptives

Aranelle
Aviane-28
Beyaz
Briellyn
Camila
Daysee
Depo-Provera
Depo-SubQ Provera
Desogestrel/ethinyl estradiol
Enpresse-28
Femhrt
Gildagia
Gildess 24 FE
Junel
Levonest
Liletta
Lo Loestrin Fe
Loryna
LoSeasonique
Low-Ogestrel-28
Mirena
Mono-Linyah
Natazia
Nexplanon
NuvaRing
Plan B One-Step
Provera
Seasonale
Seasonique
Skyla
Sprintec
Tri-Lo-Estarylla
Tri-Lo-Sprintec
Tri-Sprintec
Velvet
Xulane
Yasmin
Yaz
Zovia 1/50E-28

Z79.4 Long term (current) use of insulin

Admelog
Apidra
Basaglar
Fiasp
Humalog
Humulin R
Lantus
Levemir
Novolin
Novolog
Soliqua
Toujeo Solostar
Tresiba
Xultophy 100/3.6

Z79.51 Long term (current) use of inhaled steroids

Advair
AirDuo RespiClick
Alvesco
Arnuity Ellipta
Asmanex
Breo Ellipta
Dulera
Flovent HFA
Pulmicort
Qvar Redihaler
Symbicort
Trelegy Ellipta

Z79.52 Long term (current) use of systemic steroids

Agamree
Celestone Soluspan
Colocort
Cortef
Cortenema
Cortifoam
Depo-Medrol
Dexamethasone Intensol
Entocort EC
Hydrocortisone
Kenalog-10
Kenalog-40
Locoid
Medrol
Methylprednisolone
Orapred ODT
PediaPred
Prednisolone
Prednisone
Rayos
Solu-Cortef
Solu-Medrol

Z79.61 Long term (current) use of immunomodulator

Otezla
Pomalyst
Revlimid
Thalomid


Z79.620 Long term (current) use of immunosuppressive biologic

Actemra
Aimovig
Beyfortus
Briumvi
Columvi
Cosentyx
Cyltezo
Dupixent
Elrrexio
Enbrel
Entyvio
Epkinaly
Humira
Hyrimoz
Imjudo
Keytruda
Loqtorzi
Monoclonal antibodies
Omvoh
Prolia
Remicade
Rituxan
Simulect
Skyrizi
Stelara
Taltz
Tremfya
Xgeva

Z79.621 Long term (current) use of calcineurin inhibitor

Astagraf XL
Cyclosporine
Envarsus XR
Gengraf
Lupkynis
Neoral
Prograf
Protopic
Restasis
Sandimmune
Tacrolimus

Internal Carotid and Vertebral Arteries and Branches



External Carotid Artery and Branches

